Ondine BiomedicalFRA:VF5 37 PB Ratio is 37.50 as of Jul. 12, 2026, which is 251% above its 10-year median of 10.69. GuruFocus rates FRA:VF5 with a GF Score™ of 37/100 and a GF Value™ of €0.09 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 1,231 Biotechnology companies, Ondine Biomedical ranks worse than 96.02% on this metric.
Ondine Biomedical Inc stock PB Ratio (=36.25) is close to 5-year high of 37.5.
The historical rank and industry rank for Ondine Biomedical's PB Ratio or its related term are showing as below:
FRA:VF5'
s PB Ratio Range Over the Past 10 Years
Min: 2.22 Med: 10.69 Max: 37.5
Current: 36.25
During the past 13 years, Ondine Biomedical's highest PB Ratio was 37.50. The lowest was 2.22. And the median was 10.69.
FRA:VF5's PB Ratio is ranked worse than 96.02% of 1231
companies
in the Biotechnology industry
Industry Median: 2.93
vs FRA:VF5: 36.25
During the past 12 months, Ondine Biomedical's average Book Value Per Share Growth Rate was -55.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -51.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Ondine Biomedical was -9.00% per year. The lowest was -71.60% per year. And the median was -46.50% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Ondine Biomedical PB Ratio Related Terms
Ondine Biomedical PB Ratio Historical Data
* Premium members only.
The historical data trend for Ondine Biomedical's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ondine Biomedical's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ondine Biomedical PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ondine Biomedical's PB Ratio distribution charts can be found below:
* The bar in red indicates where Ondine Biomedical's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Ondine Biomedical (FRA:VF5) has a PB Ratio of 37.50 as of Jul. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Ondine Biomedical and its competitors. This is 251% above median its historical median of 10.69. Over the past decade, Ondine Biomedical's PB Ratio has ranged from 2.22 to 37.50. According to the industry distribution chart, Ondine Biomedical ranks #1182 out of 1231 companies in the Biotechnology industry, placing it in the top 96%.
Is Ondine Biomedical's PB Ratio too high?
Ondine Biomedical's current PB Ratio of 37.50 is 251% above median its 10-year median of 10.69. Over the past 10 years, this metric has ranged from a low of 2.22 to a high of 37.50. The Biotechnology industry median PB Ratio is 2.93. Ondine Biomedical's value of 37.50 is 1179.9% above this industry median. Based on the distribution chart, Ondine Biomedical ranks #1182 out of 1231 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ondine Biomedical has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ondine Biomedical's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ondine Biomedical ranks #1182 out of 1231 companies for PB Ratio. This places Ondine Biomedical in the lower half of its industry. The industry median PB Ratio is 2.93. Ondine Biomedical's value of 37.50 is 1179.9% above this benchmark. Historically, Ondine Biomedical's own PB Ratio has ranged from 2.22 to 37.50 over the past decade. While the company's 10-year median is 10.69 vs. the industry median of 2.93, Ondine Biomedical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,231 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ondine Biomedical's current PB Ratio of 37.50 is 1179.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Ondine Biomedical and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ondine Biomedical's current PB Ratio is 37.50, which is 251% above median its own 10-year median of 10.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ondine Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Ondine Biomedical (FRA:VF5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.09, compared to a current price of €0.15 — trading 66.7% above its estimated fair value. The current PB Ratio is 37.50, which is 251% above median its 10-year median of 10.69 and 1179.9% above the Biotechnology industry median of 2.93. Ondine Biomedical's overall GF Score™ is 37/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Ondine Biomedical (FRA:VF5), the current PB Ratio is 37.50 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ondine Biomedical (FRA:VF5) Overvalued in 2026?
Based on GuruFocus' analysis, Ondine Biomedical stock appears to be overvalued.
The current stock price of €0.15 is trading 66.7% above its estimated GF Value™ of €0.09.
GuruFocus considers Ondine Biomedical to be Significantly Overvalued.
Key valuation signals for FRA:VF5:
PB Ratio: 37.50 (251% above median its 10-year median of 10.69)
GF Value™: €0.09 vs. price of €0.15 (66.7% above fair value)
Industry Position: 1179.9% above the Biotechnology median (#1182 of 1231)
No single metric tells the full story. See the FRA:VF5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.
37GF Score
Get the complete analysis for FRA:VF5
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VF5 has been successfully added to your 
